Skip to main content
Caplight Logo









Aldebaran Therapeutics

Aldebaran Therapeutics

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://aldebarantx.com/

Last Round

Accelerator

Feb 9, 2022

Total Funding Raised

$800,000

Company Overview

Aldebaran Therapeutics is a biotechnology company that leverages human genetics and antisense oligonucleotide technology to develop precision ocular medicines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antisense oligonucleotideASOgenetic medicineocular diseaseprecision medicinebiotechdrug discoveryophthalmologygene therapypre-clinical biotechventure studiotherapeutic platformbiotech startupasset-centric biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aldebaran Therapeutics Comparables

Compare Aldebaran Therapeutics with similar companies based on industry and business-model similarity.

Aldebaran Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Broadwing Bio
78%
Isarna Therapeutics
76%
City Therapeutics
70%

Aldebaran Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorFeb 9, 2022

Aldebaran Therapeutics Investors

Notable investors and investment history

Aldebaran Therapeutics investors
InvestorRounds
82VSAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 21, 2024

    Monthly visitors increased 2110% to 221.

  • Oct 30, 2024

    Monthly visitors grew 151% MoM, from 53 to 133.

Aldebaran Therapeutics Filings

Explore SEC and related filing metadata, where available.

Aldebaran Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Aldebaran Therapeutics's valuation, stock price, and market status.

Is Aldebaran Therapeutics a public or private company?

Aldebaran Therapeutics is a private company.

What is the current stock price of Aldebaran Therapeutics?

Aldebaran Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Aldebaran Therapeutics worth (valuation)?

Valuation information for Aldebaran Therapeutics is not publicly available.

Can I buy Aldebaran Therapeutics stock?

Aldebaran Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Aldebaran Therapeutics's last funding round?

Aldebaran Therapeutics's most recent funding round was Accelerator on February 9, 2022.

Who are the main investors in Aldebaran Therapeutics?

Key investors in Aldebaran Therapeutics include 82VS.

Will Aldebaran Therapeutics IPO soon?

No public IPO plans have been announced for Aldebaran Therapeutics.

How can I track Aldebaran Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Aldebaran Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range5
Year Founded2022
Last FundingFeb 9, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?